Mary Teeling
Research Subjects
Mary Teeling has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen Bennett
Data Science Centre, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland
4 shared publications J. Feely
St. James’s Hospital
2 shared publicationsJohn Feely
Department of Pharmacology and Therapeutics, Trinity College/St James's Hospital and
2 shared publicationsK. Bennett
St. James’s Hospital
2 shared publications- Fahad Wali Ahmed
King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia
1 shared publication Humphrey O'Connor
Department of Gastroenterology, the Adelaide, Meath, National Childrens Hospital (AMNCH) Tallaght, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 6 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32248
The Prevalence of Chronic Kidney Disease and Albuminuria in Patients With Type 1 and Type 2 Diabetes Attending a Single Centre
Diabetes is the leading cause of chronic kidney disease worldwide. Diabetic kidney disease is one of the microvascular complications of diabetes and it involves changes in glomerular hemodynamics, interstitial fibrosis, and tubular atrophy. Early detection and management of Diabetic kidney disease (DKD) help to reduce morbidity and mortality. This study aims to assess the prevalence of nephropathy and albuminuria in the diabetic population attending an Irish tertiary care center. Retrospective data collection and analysis of patients diagnosed with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) through the Development and Integration of Accurate Mathematical Operations in Numerical Data-Processing (DIAMOND) database in a single Irish tertiary care center. An audit tool was used to collect patients’ information including gender, age, type of diabetes, serum creatinine, urinary albumin excretion, albumin creatinine ratio (ACR), body mass index, and last available glycated hemoglobin (HbA1c). Out of 7394 subjects with T2DM, 3139 (42%) were identified with chronic kidney disease (CKD). There were 1866 subjects with positive ACR out of 3139 subjects with CKD in the T2DM cohort. This shows that 25% of subjects have diabetic kidney disease and 17% have CKD of undetermined etiology. In the T1DM cohort with 1166 subjects, 209 (18%) were identified with CKD. Out of these 209 subjects with CKD, 164 (14%) were ACR-positive. The prevalence of CKD and albuminuria were related to age in both T1DM and T2DM populations. Albuminuria showed a linear relationship with age in subjects with no known CKD, which shows that age causally relates to albuminuria independent of type and duration of diabetes. CKD is more prevalent in patients with T2DM as compared to T1DM, whereas the prevalence of albuminuria is higher in the T1DM population.
- 6 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32248
Open AccessThe Prevalence of Chronic Kidney Disease and Albuminuria in Patients With Type 1 and Type 2 Diabetes Attending a Single Centre
Diabetes is the leading cause of chronic kidney disease worldwide. Diabetic kidney disease is one of the microvascular complications of diabetes and it involves changes in glomerular hemodynamics, interstitial fibrosis, and tubular atrophy. Early detection and management of Diabetic kidney disease (DKD) help to reduce morbidity and mortality. This study aims to assess the prevalence of nephropathy and albuminuria in the diabetic population attending an Irish tertiary care center. Retrospective data collection and analysis of patients diagnosed with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) through the Development and Integration of Accurate Mathematical Operations in Numerical Data-Processing (DIAMOND) database in a single Irish tertiary care center. An audit tool was used to collect patients’ information including gender, age, type of diabetes, serum creatinine, urinary albumin excretion, albumin creatinine ratio (ACR), body mass index, and last available glycated hemoglobin (HbA1c). Out of 7394 subjects with T2DM, 3139 (42%) were identified with chronic kidney disease (CKD). There were 1866 subjects with positive ACR out of 3139 subjects with CKD in the T2DM cohort. This shows that 25% of subjects have diabetic kidney disease and 17% have CKD of undetermined etiology. In the T1DM cohort with 1166 subjects, 209 (18%) were identified with CKD. Out of these 209 subjects with CKD, 164 (14%) were ACR-positive. The prevalence of CKD and albuminuria were related to age in both T1DM and T2DM populations. Albuminuria showed a linear relationship with age in subjects with no known CKD, which shows that age causally relates to albuminuria independent of type and duration of diabetes. CKD is more prevalent in patients with T2DM as compared to T1DM, whereas the prevalence of albuminuria is higher in the T1DM population.
- 20 July 2017
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 187 (2) , 281-285
Impact of safety warnings on domperidone prescribing in Ireland
This study aimed to investigate the impact of the 2014 safety warnings on use of domperidone, on subsequent prescribing patterns in Ireland.
- 20 July 2017
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 187 (2) , 281-285
Impact of safety warnings on domperidone prescribing in Ireland
This study aimed to investigate the impact of the 2014 safety warnings on use of domperidone, on subsequent prescribing patterns in Ireland.
- 25 May 2014
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 184 (2) , 403-410
Regional variation in medication-taking behaviour of new users of oral anti-hyperglycaemic therapy in Ireland
Few studies have investigated regional variation in medication-taking behaviour. The purpose of this study was to investigate whether there are regional differences in non-persistence and non-adherence to oral anti-hyperglycaemic agents in patients initiating therapy and examine if any association exists between different types of comorbidity in terms of medication-taking behaviour. The Irish Health Services Executive (HSE) pharmacy claims database was used to identify new users of metformin or sulphonylureas, aged ≥25 years, initiating therapy between June 2009 and December 2010. Non-persistence and non-adherence were examined up to 12 months post-initiation. Comorbidity was assessed using modified RxRisk and RxRisk-V indices, and classified as either concordant and/or discordant with diabetes. Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for non-persistence were determined in relation to both HSE region and comorbidity type using Cox proportional hazards model, adjusting for age, sex and initial OAH prescribed. Logistic regression analysis, adjusting for these covariates, was used to determine the adjusted odds ratios (ORs) and 95 % CIs for non-adherence for both HSE region and comorbidity type. Results showed little overall difference between regions. The largest reduction for both non-persistence (HR 0.86, 95 % CI 0.80, 0.94) and non-adherence (OR 0.83, 95 % CI 0.74, 0.93) was observed in the south. Any comorbidity was associated with a reduced risk of non-persistence and non-adherence. Interventions to optimise medication-taking in patients with T2DM should be implemented nationally to improve the overall level of adherence and persistence, especially in patients with no comorbidity.
- 25 May 2014
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 184 (2) , 403-410
Regional variation in medication-taking behaviour of new users of oral anti-hyperglycaemic therapy in Ireland
Few studies have investigated regional variation in medication-taking behaviour. The purpose of this study was to investigate whether there are regional differences in non-persistence and non-adherence to oral anti-hyperglycaemic agents in patients initiating therapy and examine if any association exists between different types of comorbidity in terms of medication-taking behaviour. The Irish Health Services Executive (HSE) pharmacy claims database was used to identify new users of metformin or sulphonylureas, aged ≥25 years, initiating therapy between June 2009 and December 2010. Non-persistence and non-adherence were examined up to 12 months post-initiation. Comorbidity was assessed using modified RxRisk and RxRisk-V indices, and classified as either concordant and/or discordant with diabetes. Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for non-persistence were determined in relation to both HSE region and comorbidity type using Cox proportional hazards model, adjusting for age, sex and initial OAH prescribed. Logistic regression analysis, adjusting for these covariates, was used to determine the adjusted odds ratios (ORs) and 95 % CIs for non-adherence for both HSE region and comorbidity type. Results showed little overall difference between regions. The largest reduction for both non-persistence (HR 0.86, 95 % CI 0.80, 0.94) and non-adherence (OR 0.83, 95 % CI 0.74, 0.93) was observed in the south. Any comorbidity was associated with a reduced risk of non-persistence and non-adherence. Interventions to optimise medication-taking in patients with T2DM should be implemented nationally to improve the overall level of adherence and persistence, especially in patients with no comorbidity.
- Open Access
- 15 August 2007
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (4) , 536-541
What therapies have replaced rofecoxib in Ireland?
- 15 August 2007
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (4) , 536-541
Open AccessWhat therapies have replaced rofecoxib in Ireland?
- 1 June 2006
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 175 (2) , 46-49
Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation.
- 1 June 2006
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 175 (2) , 46-49
Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation.
- Open Access
- 26 January 2005
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (2) , 227-232
The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002
Aims: To monitor statin prescribing trends over time in order to determine whether prescribers were influenced by study results and/or clinical guidelines in terms of type and dosage of statin prescribed.Methods: The GMS (General Medical Services) prescription database in Ireland was used to identify a cohort of patients, prescribed statins, in order to investigate prescribing trends from January 1998–December 2002. Statin prescribing rates for patients with ischaemic heart disease and diabetes were compared with rates in the general GMS population. Logistic regression analysis was used in patients with ischaemic heart disease and diabetes and adjusted odds ratios and 95% confidence intervals presented.Results: Increased statin prescribing over time was noted (test for linear trend P < 0.0001). Pravastatin was the most frequently prescribed, followed by atorvastatin; simvastatin and fluvastatin showed lower rates of prescribing. Atorvastatin showed the greatest increased rate over time. An increase in the overall dose prescribed (test for trend P < 0.01) was chiefly due to increases in pravastatin dose, but doses were still below those recommended from clinical trials. Statins were prescribed more frequently in patients with ischaemic heart disease and diabetes, 44% (95% CI 43–45%) compared with the total GMS population, 7.7% (95% CI 7.6–7.8%), by December 2002. However, statins were only prescribed to 52% (95% CI 51–53%) of ischaemic heart disease patients and 40% (95% CI 39–41%) of patients with diabetes by December 2002. Patients aged 45–64 years were more likely to receive statins, compared with those aged 65 years and older.Conclusion: These findings suggest that the beneficial effects of statins shown in clinical studies may not be achieved in practice.
- 26 January 2005
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (2) , 227-232
Open AccessThe influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002
Aims: To monitor statin prescribing trends over time in order to determine whether prescribers were influenced by study results and/or clinical guidelines in terms of type and dosage of statin prescribed.Methods: The GMS (General Medical Services) prescription database in Ireland was used to identify a cohort of patients, prescribed statins, in order to investigate prescribing trends from January 1998–December 2002. Statin prescribing rates for patients with ischaemic heart disease and diabetes were compared with rates in the general GMS population. Logistic regression analysis was used in patients with ischaemic heart disease and diabetes and adjusted odds ratios and 95% confidence intervals presented.Results: Increased statin prescribing over time was noted (test for linear trend P < 0.0001). Pravastatin was the most frequently prescribed, followed by atorvastatin; simvastatin and fluvastatin showed lower rates of prescribing. Atorvastatin showed the greatest increased rate over time. An increase in the overall dose prescribed (test for trend P < 0.01) was chiefly due to increases in pravastatin dose, but doses were still below those recommended from clinical trials. Statins were prescribed more frequently in patients with ischaemic heart disease and diabetes, 44% (95% CI 43–45%) compared with the total GMS population, 7.7% (95% CI 7.6–7.8%), by December 2002. However, statins were only prescribed to 52% (95% CI 51–53%) of ischaemic heart disease patients and 40% (95% CI 39–41%) of patients with diabetes by December 2002. Patients aged 45–64 years were more likely to receive statins, compared with those aged 65 years and older.Conclusion: These findings suggest that the beneficial effects of statins shown in clinical studies may not be achieved in practice.
- 3 February 2004
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (3) , 337-343
Have COX‐2 inhibitors influenced the co‐prescription of anti‐ulcer drugs with NSAIDs?
Aims To quantify usage of COX-2 inhibitors compared with nonselective NSAIDs and to determine their impact (including financial) on the co-prescription of antipeptic ulcer (anti-PU) drugs. Methods The Irish General Medical Services prescription database (covering 1.2 million people) was examined for NSAID prescriptions during December 1999-November 2001. NSAID users were excluded during the first 6 months. During the next 12 months (study period) patients on NSAIDs (≥ 3 prescriptions) were identified. The study period and final 6 months provided data on co-prescription of anti-PU drugs. Age, gender, number of concomitant prescriptions, co-prescribing of anti-PU drugs and monthly cost were evaluated for 8 NSAIDs (n= 4 non-selective NSAIDs and n= 4 COX-2 inhibitors) and odds ratios (OR) calculated using logistic regression. Results COX-2 inhibitors were prescribed more frequently in older, female patients and those receiving multiple medications. After adjustment for age, gender and polypharmacy, anti-PU drugs were prescribed more frequently with COX-2 inhibitors (OR = 1.31 (1.23,1.40)). COX-2 inhibitors were up to 10-fold more expensive, median monthly costs (including anti-PU drugs) ranging from €34.61 (COX-2 inhibitors) to €3.26 (nonselective NSAIDs). Conclusions Since COX-2 inhibitors are associated with increased rates of co-prescription of anti-PU drugs and are more expensive than non-selective NSAIDs, these results suggest that the expected cost-savings with COX-2 inhibitors may not be occurring in practice.
- 3 February 2004
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (3) , 337-343
Have COX‐2 inhibitors influenced the co‐prescription of anti‐ulcer drugs with NSAIDs?
Aims To quantify usage of COX-2 inhibitors compared with nonselective NSAIDs and to determine their impact (including financial) on the co-prescription of antipeptic ulcer (anti-PU) drugs. Methods The Irish General Medical Services prescription database (covering 1.2 million people) was examined for NSAID prescriptions during December 1999-November 2001. NSAID users were excluded during the first 6 months. During the next 12 months (study period) patients on NSAIDs (≥ 3 prescriptions) were identified. The study period and final 6 months provided data on co-prescription of anti-PU drugs. Age, gender, number of concomitant prescriptions, co-prescribing of anti-PU drugs and monthly cost were evaluated for 8 NSAIDs (n= 4 non-selective NSAIDs and n= 4 COX-2 inhibitors) and odds ratios (OR) calculated using logistic regression. Results COX-2 inhibitors were prescribed more frequently in older, female patients and those receiving multiple medications. After adjustment for age, gender and polypharmacy, anti-PU drugs were prescribed more frequently with COX-2 inhibitors (OR = 1.31 (1.23,1.40)). COX-2 inhibitors were up to 10-fold more expensive, median monthly costs (including anti-PU drugs) ranging from €34.61 (COX-2 inhibitors) to €3.26 (nonselective NSAIDs). Conclusions Since COX-2 inhibitors are associated with increased rates of co-prescription of anti-PU drugs and are more expensive than non-selective NSAIDs, these results suggest that the expected cost-savings with COX-2 inhibitors may not be occurring in practice.